Status:
COMPLETED
Thrombelastography Based Dosing of Enoxaparin
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Medical Research Foundation, Oregon
National Trauma Research Institute
Conditions:
Thromboembolic Complications
Eligibility:
All Genders
15+ years
Phase:
NA
Brief Summary
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their le...
Detailed Description
Hypothesis: Enoxaparin dosed to maintain a TEG® ΔR greater than 1.0 minute will decrease the incidence of DVT compared to standard dosing. Initiation of enoxaparin thromboprophylaxis will be done by...
Eligibility Criteria
Inclusion
- Inpatient initiated on enoxaparin thromboprophylaxis
- Age greater than 15 years
Exclusion
- Unable to obtain consent from patient or ARR
- Presence of: intracranial hemorrhage, brain injury
- Receiving therapeutic dose enoxaparin
- Receiving other forms of anticoagulation
- Receiving non-standard dosing regimen of enoxaparin
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT00990236
Start Date
September 1 2009
End Date
March 1 2015
Last Update
April 3 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239
2
University of Texas Health Science Center at Houston
Houston, Texas, United States
3
University of Washington
Seattle, Washington, United States